PPP1R13B (Protein Phosphatase 1 Regulatory Subunit 13B), also known as iASPP (inhibitor of Apoptosis Stimulating Protein of p53), is a regulatory protein involved in apoptosis, stress response, and tumorigenesis. It functions as an inhibitor of p53 and NF-κB transcriptional activity by binding to their transactivation domains, thereby modulating cell survival and death pathways. PPP1R13B is overexpressed in several cancers, where it suppresses apoptosis and promotes chemoresistance, making it a potential therapeutic target.
Antibodies targeting PPP1R13B are essential tools for studying its expression, localization, and interactions in cellular models and clinical samples. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess PPP1R13B levels in cancer tissues, correlate its expression with disease progression, or evaluate its role in cellular stress responses. Some studies also employ PPP1R13B antibodies in co-immunoprecipitation (Co-IP) to explore its binding partners, such as p53 or PP1 phosphatase.
Research using PPP1R13B antibodies has highlighted its dual role: while it promotes survival in normal cells under stress, its dysregulation in cancer contributes to tumor aggressiveness. Recent work focuses on developing inhibitors that disrupt PPP1R13B-p53 interactions to reactivate apoptosis in malignancies. Validated antibodies are critical for these investigations, requiring specificity checks via knockout controls or siRNA knockdown to ensure accuracy in experimental outcomes.